Loading search results

Outcome Measures

Primary Outcomes (4)

Maximum Observed Analyte Concentration (Cmax) of Selexipag and ACT-333679
The Cmax is the maximum observed analyte concentration.
Predose and 0 to 72 hours postdose
Area Under Analyte Concentration From Time Zero to the Last Quantifiable Concentration (AUC [0-last]) of Selexipag and ACT-333679
AUC (0-last) defined as the area under the analyte concentration-time curve from time zero to time of the last measurable (non-BQL) analyte concentration, calculated by linear-linear trapezoidal summation.
Predose and 0 to 72 hours postdose
Plasma analyte concentration 24 hours (C24) Post Dose of Selexipag and ACT-333679
C24 defined as plasma analyte concentration at 24 hours postdose.
Predose and 0 to 72 hours postdose
Area Under the Analyte Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])
AUC (0-infinity) is defined the area under the analyte concentration-time curve from time zero to infinity time, calculated as the sum of AUC (0-last) and C(last)/lambda(z); wherein AUC (0-last) is area under the plasma concentration-time curve from time zero to last measurable concentration, C(last) is the last observed measurable concentration, and lambda(z) is apparent terminal elimination rate constant.
Predose and 0 to 72 hours postdose

Secondary Outcomes (1)

Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Up to 50 Days

Study Arms (2)

Cohort 1: Selexipag Matrix Tablets

EXPERIMENTAL

Participants will receive oral doses of selexipag matrix tablets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.

Drug: Selexipag matrix tabletDrug: Selexipag Immediate-release (IR) tablet

Cohort 2: Selexipag Encapsulated Pellets

EXPERIMENTAL

Participants will receive oral doses of selexipag encapsulated) pellets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.

Interventions

Selexipag matrix tabletDrug

Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.

Also known as: JNJ-67896049

Cohort 1: Selexipag Matrix Tablets

Selexipag encapsulated pelletsDrug

Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.

Eligibility Criteria

Age18 Years - 55 Years

Sexmale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening
Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the participants may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator

A Study of Selexipag in Healthy Male Participant

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (1)

Study Arms (2)

Cohort 1: Selexipag Matrix Tablets

Cohort 2: Selexipag Encapsulated Pellets

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (1)

Study Arms (2)

Cohort 1: Selexipag Matrix Tablets

Cohort 2: Selexipag Encapsulated Pellets

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations